

Article

Senior Fitness Test in the Assessment of Functional Fitness in Patients with Parkinson's Disease at Different Levels of Physical Activity

Jaroslav Cholewa ^{1,*}, Ivan Uher ² , Joanna Cholewa ³, Jacek Polechonski ³ , Grzegorz Mikrut ⁴  and Agnieszka Gorzkowska ⁵ 

¹ Institute of Physical Education and Health, University of Applied Sciences in Raciborz, 47-400 Raciborz, Poland

² Institute of Physical Education and Sport, Pavol Jozef Safarik University in Kosice, 041 80 Kosice, Slovakia; ivan.uher@upjs.sk

³ Institute of Sport Sciences, Academy of Physical Education in Katowice, 40-065 Katowice, Poland; a.cholewa@awf.katowice.pl (J.C.); j.polechonski@awf.katowice.pl (J.P.)

⁴ Department of Sport Management, Faculty of Physical Education and Sport, Charles University, 162 52 Prague, Czech Republic; grzegorz.mikrut@ftvs.cuni.cz

⁵ Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, 40-752 Katowice, Poland; agorzkowska@sum.edu.pl

* Correspondence: jaroslav.cholewa@akademiarac.edu.pl

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a decline in functional capacity and increasing limitations in daily activities. Clinical assessment tools provide valuable information on symptom severity but do not fully capture functional capacity. The aim of this study was to determine the usefulness of the Senior Fitness Test (SFT) for assessing functional capacity in patients with PD, based on whether they met (Group A) or did not meet (Group B) health-promoting physical activity (PA) recommendations. The study included 74 patients with idiopathic PD classified as Hoehn and Yahr stage II. PA was assessed using ActiGraph GT3X+ triaxial accelerometer and activity diaries, functional capacity using SFT, and symptom severity by MDS-UPDRS scale. Group A achieved significantly better results in all SFT components and had lower MDS-UPDRS scores than group B. The synthetic functional index was higher in the A group (1.28 ± 2.25 vs. -0.64 ± 2.28 ; $p < 0.001$), whereas the total MDS-UPDRS score was lower (31.09 ± 4.97 vs. 34.99 ± 5.28 ; $p = 0.022$). The results indicate that the SFT may be a useful and practical tool to complement the clinical assessment of patients with PD and may support more individualized rehabilitation planning and monitoring.

Keywords: Parkinson's disease; Senior Fitness Test; functional fitness; physical activity; MDS-UPDRS; rehabilitation; accelerometry; functional capacity; exercise



Academic Editor: Argyris Toubekis

Received: 7 May 2026

Revised: 4 July 2026

Accepted: 7 July 2026

Published: 11 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by worsening motor impairment and a gradual decline in functional fitness and independence [1,2]. Although its most characteristic clinical symptoms include bradykinesia, rigidity, resting tremor, and postural instability, the overall burden of the disease is most clearly reflected in the decreasing ability to perform basic activities of daily living. This leads to reduced daily activity and poorer quality of life [3,4]. Therefore, assessing functional fitness in relation to

physical activity (PA) levels may provide clinically relevant information about the everyday functioning of patients with PD.

PA is considered an important component of comprehensive non-pharmacological management in PD. Scientific evidence indicates that aerobic training, resistance training, balance exercises, and multicomponent programs may improve motor function, mobility, functional fitness, and selected aspects of quality of life [5–7]. However, the relationship between adherence to PA recommendations and functional fitness, as assessed using simple clinical tools, remains underexplored in patients with PD [7]. Despite the growing body of research, there remains a need for tools that enable assessment of both the severity of disease symptoms and actual functional capacity, as well as the effects of exercise interventions [8,9]. In clinical practice, one of the basic instruments used to assess patient status is the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), which is recognized as a standard measure of symptom severity and motor complications [10]. Although the MDS-UPDRS provides important clinical information, it does not fully capture functional abilities for everyday motor tasks, including lower and upper body strength, flexibility, dynamic balance, agility, and aerobic endurance. Previous studies have indicated that the Senior Fitness Test (SFT) may be useful for assessing functional fitness in patients with PD [11,12]. However, it remains unclear whether the SFT can detect differences in functional fitness based on adherence to health-promoting physical activity recommendations. Therefore, clinical assessment may be usefully complemented by physical fitness tests that reflect the ability to perform functional tasks.

SFT is a simple, standardized battery that assesses lower and upper body strength, flexibility, dynamic balance, agility, and aerobic endurance. Because these domains are directly related to activities of daily living, the SFT may provide valuable complementary information to symptom-based clinical assessment in patients with PD [11,12]. Unlike the MDS-UPDRS, which primarily evaluates symptom severity and motor complications, the SFT measures performance in functional motor tasks that reflect everyday physical abilities. Consequently, it may help identify functional limitations that are not fully captured by clinical rating scales and support individualized rehabilitation planning and monitoring. Patients with similar disease duration or the same Hoehn and Yahr stage may differ considerably in strength, balance, mobility, endurance, and flexibility. Therefore, performance-based functional assessment may provide additional insight into everyday functioning beyond neurological evaluation alone [11,13,14].

Although the MDS-UPDRS provides valuable information about symptom severity and motor complications, it does not directly measure functional capacity through the performance of specific motor tasks. Patients with a similar disease duration or the same Hoehn and Yahr stage may still differ considerably in strength, balance, mobility, endurance, and flexibility. For this reason, performance-based tests can provide additional information that is not fully captured by clinical rating scales [11,15].

It has been shown that daily PA may play an important role in shaping functional status in patients with PD by supporting functional fitness, but insufficient activity may contribute to progressive functional limitations and greater dependence in activities of daily living [6,16,17]. Therefore, even among patients at a similar stage of disease progression, meeting or not meeting health-promoting physical activity recommendations may clearly differentiate physical fitness and clinical status. Functional fitness is an important component of everyday functioning in patients with PD, and its assessment may provide clinically relevant information to support rehabilitation planning.

Previous studies have demonstrated the usefulness of the SFT in patients with PD; however, its ability to differentiate functional fitness according to adherence to health-promoting physical activity recommendations has not yet been sufficiently investigated.

We hypothesized that patients with PD who meet physical activity recommendations would perform better across all SFT components than those who do not. Therefore, this study may provide additional evidence on the usefulness of the SFT as a practical tool for identifying functional differences related to PA level and for supporting individualized rehabilitation planning.

The aim of this study was to determine the usefulness of the Senior Fitness Test in assessing functional fitness in patients with PD who either met or did not meet health-promoting physical activity recommendations.

2. Materials and Methods

A cross-sectional observational study was conducted 85 patients diagnosed with idiopathic PD according to the MDS Clinical Diagnostic Criteria [18]. Due to incomplete data, 11 were excluded from the final analysis, which included 74 patients (age 63.49 ± 7.43 years, disease duration 6.93 ± 3.08 years, classified as Hoehn and Yahr stage II [19]).

All participants were informed about the study procedures and provided written informed consent. Participants were recruited by purposive sampling from Parkinson's disease associations in the Silesian region of Poland. Medical supervision was maintained for all participants. Primary pharmacological treatment consisted of levodopa; ropinirole or piribedil was added as indicated. The levodopa equivalent daily dose (LED) was calculated using conversion factors reported in the literature [20].

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Bioethics Committee of the Academy of Physical Education in Katowice (approval no. 30/2017). Required sample size was estimated using a sample size calculator for comparing two independent groups. Assuming a two-tailed test, an expected medium to large effect size (Cohen's $d = 0.70$), a significance level of $\alpha = 0.05$, and statistical power of $1 - \beta = 0.80$. A final sample of 74 participants was considered sufficient for the planned between-group comparisons and correlation analyses.

Inclusion criteria were: idiopathic PD diagnosed according to the MDS Clinical Diagnostic Criteria [18]; disease stage II on the Hoehn and Yahr scale [19]; Mini-Mental State Examination (MMSE) score ≥ 24 [21]; and Beck Depression Inventory (BDI) score < 10 [22]. Exclusion criteria comprised Parkinsonian syndromes other than idiopathic PD, coexisting neurodegenerative disorders, and medical conditions or comorbidities that reduced exercise tolerance or contraindicated physical exertion.

Clinical status was assessed using the MDS-UPDRS, including Part II: Motor Experiences of Daily Living (ME-DL), Part III: Motor Examination (ME), and Part IV: Motor Complications (MC) [10].

Weekly PA was measured with a triaxial ActiGraph GT3X+ accelerometer [23,24], which recorded accelerations in the sagittal, frontal, and transverse planes. To minimize the impact of seasonal variation, accelerometer based measurements were performed during the transitional seasons (October and March), in accordance with PA assessment guidelines [25]. Devices were worn on the hip for seven consecutive days and were removed only for sleep and water related activities, following the methodology of Ito et al. [26]. Accelerometer data were processed using ActiLife 5.10.0 software. Only records meeting predefined criteria for reliable monitoring were included in the analysis. A valid measurement day was defined as ≥ 10 h of wear time. Non wear time was defined as ≥ 60 consecutive minutes of zero counts and was excluded from the dataset. Data were analyzed in 60-s epochs. PA intensity was classified using Freedson cut-points for adults: sedentary 0–99 counts/min; light 100–1951 counts/min; moderate 1952–5724 counts/min; and vigorous ≥ 5725 counts/min [27].

During the monitoring week, a PA diary was completed by each participant to record duration, type, and intensity of daily activities. Subjective intensity was recorded on a three level scale (low, moderate, high). The diary included descriptions and examples to facilitate accurate reporting. Participation in individual, organized, and rehabilitation based activities was recorded; diary entries were compared with accelerometer data for verification.

Participants were stratified into two groups according to adherence to PA guidelines jointly developed by the Parkinson's Foundation and the American College of Sports Medicine (ACSM) [28]. Group A ($n = 23$) comprised patients who met the minimum criteria for health promoting physical activity (primarily ≥ 150 min/week of moderate to vigorous PA, with documented strength and balance exercises as recorded in the diary). Participants who did not meet all these criteria were classified as not meeting the recommendations (Group B, $n = 51$).

PA recommendations applied in this study were as follows: aerobic training—3 days per week, 20–60 min per session, moderate to high intensity (e.g., brisk walking, stationary cycling, treadmill, swimming); resistance training—2–3 days per week, 10–15 repetitions for major muscle groups, 1–3 sets per group; balance/agility/coordination exercises—2–3 days per week (e.g., tai chi, yoga, functional training); stretching/flexibility—daily or at least 2–3 times per week, holding each position for 10–30 s with 2–4 repetitions.

Physical fitness was assessed using SFT, comprising six trials [29]. The Chair Stand Test was used to assess lower-body strength (number of stands in 30 s). The Arm Curl Test assessed upper body strength (2 kg weight for women, 3 kg for men; number of lifts in 30 s). The Back Scratch Test evaluated upper body flexibility as the distance between the tips of the middle fingers. The Chair Sit and Reach Test assessed lower body flexibility (distance between fingertips and toes). The Up-and-Go test measured agility and dynamic balance as the time (seconds) required to rise from a chair, walk 3 m, turn, return, and sit down. The 2-Minute Walk Test was used to assess aerobic endurance (number of full steps completed in 2 min).

A synthetic functional index (SSFT) was calculated to provide a global measure of functional capacity. Individual scores for each of the six SFT items were converted to standardized z-scores. For tests in which a lower score indicated better performance (e.g., Up-and-Go), z-scores were multiplied by -1 to ensure consistent interpretation. The SSFT for each participant was computed as the arithmetic mean of the six standardized scores, following the methodology proposed by Cancela et al. [12]. The SSFT was used to evaluate the correlation between physical fitness and PD symptom severity.

Statistical analyses were performed using STATISTICA software (version 13.3 PL; TIBCO Software Inc., Palo Alto, CA, USA). Descriptive statistics were reported as means $\pm$ standard deviations (SD). Normality of data distribution was assessed with the Kolmogorov–Smirnov test and homogeneity of variances with Levene's test. Between group differences were evaluated with independent samples *t*-tests. Pearson's correlation coefficient was used to assess relationships between the SSFT index and MDS-UPDRS scores. Effect sizes for between-group comparisons were estimated using Cohen's *d* (small = 0.2, medium = 0.5, large = 0.8). Statistical significance was set at $p < 0.05$.

3. Results

Before the analysis of physical fitness in relation to symptom severity, the two groups were compared regarding age, disease duration and daily levodopa equivalent dose. No statistically significant differences were observed between the study groups (Table 1), indicating that these parameters did not differentiate the groups.

Table 1. Characteristics of participants.

Characteristics	Group A (n = 23)	Group B (n = 51)	t-Test	
	X ± SD	X ± SD	p-Value	t
Age (years)	62.73 ± 7.41	64.24 ± 7.52	0.35	−0.94
Disease duration (years)	6.84 ± 3.06	7.02 ± 3.15	0.8	−0.25
Daily levodopa equivalent dose (mg)	721 ± 243	735 ± 297	0.67	−0.42

A—meeting the criteria for health-promoting physical activity; B—not meeting the criteria for health-promoting physical activity; X—arithmetic mean; SD—standard deviation; t—t-test value; p—probability value.

To reduce the influence of potential confounding factors, the study included only patients with Hoehn and Yahr stage II, MMSE ≥ 24 , and BDI < 10 . In addition, the study groups did not differ significantly in age, disease duration, or levodopa equivalent daily dose.

Using the MDS-UPDRS to assess disease symptom severity, Group A, which met the criteria for health-promoting PA, had significantly lower scores across all analyzed parts of the scale than Group B. The differences were observed in Motor Experiences of Daily Living (ME-DL; $p = 0.019$), Motor Examination (ME; $p = 0.044$), and Motor Complications (MC; $p = 0.010$). The total MDS-UPDRS score was also significantly lower in Group A than in Group B ($p = 0.022$) (Table 2).

Table 2. Comparison of the groups in terms of disease symptom severity (MDS-UPDRS) and physical fitness (SFT).

Parameter	Group A (n = 23)	Group B (n = 51)	t	p	Cohen_d (A-B)
MDS—UPDRS					
ME-DL [points]	6.71 ± 1.16	7.49 ± 1.19	−2.40	0.019	−0.661
ME [points]	20.46 ± 4.63	22.89 ± 4.81	−2.05	0.044	−0.511
MC [points]	3.92 ± 0.98	4.61 ± 1.12	−2.65	0.010	−0.639
MDS-UPDRS Total [points]	31.09 ± 4.97	34.99 ± 5.28	−2.34	0.022	−0.752
SFT					
Chair Stand (30 s)	12.95 ± 3.13	11.35 ± 2.95	2.07	0.045	0.532
Arm Curl (30 s)	16.01 ± 3.03	14.52 ± 2.57	2.06	0.047	0.548
Back Scratch (cm)	−1.83 ± 4.20	−4.87 ± 5.74	2.56	0.013	0.572
Chair Sit-and-Reach (cm)	1.82 ± 4.48	−1.16 ± 5.02	2.55	0.014	0.613
Up-and-Go (s)	7.41 ± 1.06	8.18 ± 1.55	−2.47	0.017	−0.543
2-Min Walk Test (n)	95.47 ± 13.19	86.93 ± 13.15	2.58	0.013	0.649
SSFT	1.28 ± 2.25	−0.64 ± 2.28	3.66	0.00057	0.845

In the SFT, Group A performed better across all six trials. The largest differences were observed in the Back Scratch test ($p = 0.013$), the Chair Sit-and-Reach test ($p = 0.014$), and the 2-Minute Walk Test ($p = 0.013$), indicating significantly better flexibility and cardiorespiratory endurance among PA participants. In the upper and lower limb strength tests, namely the Arm Curl and Chair Stand tests, the differences also reached statistical significance ($p \approx 0.045$ – 0.047). The shorter time recorded in the Up-and-Go test for Group A ($p = 0.017$) indicates better coordination and balance.

The mean SSFT was markedly higher in Group A (1.28 ± 2.25) than in Group B ($−0.64 \pm 2.28$; $p < 0.001$). The absolute effect sizes for between group differences ranged

from medium ($d = 0.51$) to large ($d = 0.85$), with the largest effect observed for the SSFT (Table 2).

To evaluate the relationship between symptom severity and physical fitness, Pearson's correlation coefficients were calculated between the SSFT index and individual MDS-UPDRS components (Part II: ME-DL, Part III: ME, Part IV: MC, and the Total score). These analyses were performed separately for Group A and Group B (Figure 1).




Figure 1. Pearson's correlation coefficients (r) between the SSFT index and the individual components of the MDS-UPDRS scale (Part II—ME-DL, Part III—ME, Part IV—MC, and Total score) in Groups A and B.

The correlation analysis revealed significant negative relationships between the SSFT index and all parts of the MDS-UPDRS scale in both groups. The strongest associations were observed for the Total MDS-UPDRS score and Part II (ME-DL), while the weakest correlations were found for Part IV (MC). Specifically, Group A showed a correlation of $r = -0.52$ ($p < 0.01$), and Group B showed $r = -0.68$ ($p < 0.001$) between the SSFT and the total MDS-UPDRS score. The negative slope shown in Figures 1 and 2 indicates that higher SSFT scores were associated with lower total MDS-UPDRS scores. This relationship was stronger in Group B, which may suggest that, among patients who did not meet PA recommendations, functional fitness was more closely related to disease symptom severity. However, the visible dispersion of data points indicates individual variability; therefore, SFT results should be interpreted as a complement to, rather than a substitute for, clinical assessment.




Figure 2. Scatter plots illustrating the relationship between the SSFT index and the total MDS-UPDRS score: (a) Group A; (b) Group B.

4. Discussion

The study examined the usefulness of SFT in assessing functional fitness in patients with PD who differed in adherence to health-promoting physical activity recommendations. The findings clearly indicate that patients who met the recommendations achieved better results across all SFT components, had a higher SSFT, and had lower MDS-UPDRS scores than patients who did not meet the recommendations. Moreover, the negative correlations between SSFT and MDS-UPDRS scores indicate that better functional fitness was associated with lower clinical severity. These results support the value of performance-based functional assessment in PD and suggest that the SFT may provide clinically useful information beyond standard symptom rating [11,12,30].

The original contribution of this study is that it evaluates the SFT as a tool capable of differentiating patients according to their adherence to health-promoting PA recommendations. In contrast to previous studies that mainly assessed the relationship between SFT performance and clinical status or rehabilitation outcomes, the present study links SFT results with objectively verified PA classification. This approach provides additional evidence that the SFT may be useful for identifying functional differences relevant to everyday activity and rehabilitation planning.

A cross-sectional design was chosen because the main aim of the study was to assess whether the SFT can differentiate functional fitness in patients with PD who either meet or do not meet health-promoting PA recommendations at a single point in time. This design was considered appropriate for the preliminary evaluation of the practical usefulness of the SFT as a tool complementing clinical assessment. The relationship between PA and functional fitness may be bidirectional; therefore, longitudinal studies are needed to determine the direction and causality of this association.

In our study, PA active patients performed better in strength, flexibility, agility, dynamic balance, and endurance. This suggests that meeting PA recommendations may be associated with broader preservation of functional capacity. Nevertheless, because the study was cross-sectional, these findings should be interpreted as associations. It cannot be concluded whether higher PA contributed to better functional fitness or whether patients with better functional capacity were more able to remain active [16,17]. Therefore, no causal relationship between PA and functional fitness can be inferred from the present results.

The present findings reinforce the practical value of this performance based assessment in patients with PD. It evaluates functional domains directly related to everyday activities, including strength, balance, mobility, flexibility, and aerobic endurance, which are essential for daily motor tasks such as standing up, walking, turning, reaching, and maintaining balance. Previous studies demonstrated significant associations between test performance and MDS-UPDRS scores [11], as well as its usefulness for evaluating the effects of physical rehabilitation on quality of life in patients with PD [31]. Its clinical relevance is further supported by evidence linking chair-rising ability and functional gait with activities of daily living and PA [13,32]. The present study extends these findings by demonstrating that the test battery can also differentiate patients according to adherence to health-promoting physical activity recommendations [28]. Among all assessed measures, the SSFT showed the greatest discriminatory ability, while the 2-Minute Walk Test, Chair Sit-and-Reach, and Back Scratch tests were the most sensitive individual components, suggesting that meeting physical activity recommendations is most strongly associated with overall functional fitness, endurance, and flexibility in patients with PD.

A main importance is the inverse relationship between SSFT and MDS-UPDRS scores. This means that patients with higher overall functional fitness tended to have lower severity of disease related symptoms and complications. The association was observed in both groups, which strengthens the interpretation that functional performance is meaningfully related to clinical status. At the same time, the relationship appeared slightly stronger among patients who did not meet physical activity recommendations. One possible explanation is that, in less active individuals, functional performance may more directly reflect the combined burden of neurological impairment, secondary deconditioning, and reduced mobility. In more active patients, regular movement may partly buffer the functional consequences of motor symptoms [5,6]. However, the direction of this relationship remains uncertain and should be tested in longitudinal studies [5–7,17].

The results also underline that functional fitness assessment may complement clinical scales. The MDS-UPDRS remains a standard and highly informative tool for assessing symptom severity and motor complications, and its clinimetric value has been well established [10]. However, it does not directly measure how well patients perform functional tasks. Functional capacity depends on neurological impairment and also on strength, endurance, balance, coordination, flexibility, and confidence in movement. Therefore, two patients with similar clinical scores may differ substantially in their ability to function independently in daily life. The SFT can help capture this task-oriented dimension of functioning. The SFT is a complementary functional assessment rather than a diagnostic instrument for classifying individual patients by their level of PA or disease status. The value of the SFT is providing complementary information on functional capacity, identifying areas of functional limitation, and monitoring changes over time in response to rehabilitation or PA interventions. It may serve as a practical supplementation between neurological assessment and real world functional performance. This approach is consistent with current rehabilitation frameworks and with recent perspectives emphasizing the need for a multidimensional understanding of PD, including lifestyle, functional capacity, and patient-related factors [1,7,33].

From a clinical and rehabilitation perspective, these findings indicate that regular PA should be considered an integral component of PD care [34]. Patients who met activity recommendations demonstrated better functional performance and lower clinical severity, which supports the relevance of maintaining movement habits beyond supervised rehabilitation sessions. The SFT may also be useful for monitoring functional status over time, as it is simple, inexpensive, and feasible in clinical, rehabilitation, and community settings. Its multidimensional structure allows clinicians to identify specific functional

deficits and adjust rehabilitation programs more precisely. Lower performance in Chair Stand or Up-and-Go may indicate the need to emphasize lower-limb strength, transfers, balance, and mobility, whereas reduced endurance may suggest the need for carefully dosed aerobic training [7,29].

In clinical practice, the SFT may be used for the initial assessment of functional fitness, for monitoring changes during rehabilitation, and for evaluating the effectiveness of exercise interventions. The interpretation of its individual components may help clinicians identify functional domains requiring priority intervention, while the SSFT may provide an additional summary measure of overall functional performance to support individualized rehabilitation planning.

We acknowledge the limitations of the study. The cross sectional observational design does not allow for conclusions about causal relationships between PA, functional ability, and disease severity. In addition, participants were recruited using purposive sampling, and the unequal group sizes may have limited the generalizability of the findings to the broader population of patients with PD. Limiting the study to patients classified as Hoehn and Yahr stage II increased sample homogeneity and reduced the potential influence of disease severity on functional fitness outcomes. However, this approach limited the generalizability of the results to patients with earlier or more advanced stages of PD. Therefore, the applicability of the SFT across the full clinical spectrum of PD requires further investigation in studies including patients at different stages of disease progression.

Implementation of an accelerometer improved the objectivity of PA assessment; however, the recorded activity levels may still have been influenced by diurnal variability, medication timing, motor fluctuations, and adherence to monitoring procedures. Furthermore, although SFT addresses important areas of functional ability, it is not specific to PD and does not directly assess disease specific symptoms such as freezing of gait, nonmotor symptoms, or motor fluctuations [35,36].

5. Conclusions

In conclusion, this study demonstrates that the SFT is a feasible and clinically relevant tool for assessing functional capacity in patients with PD and provides evidence that it can differentiate patients by adherence to health-promoting physical activity recommendations. The SFT can complement standard neurological assessment by providing objective information on functional capacity that is directly relevant to rehabilitation planning and monitoring.

The observed associations between improved functional capacity and lower MDS-UPDRS scores should be interpreted in light of the cross sectional study design, which identifies associations but not causal relationships. Nevertheless, the results support the clinical utility of the SFT in assessing key areas of functional capacity, including strength, flexibility, balance, mobility, and endurance.

Future studies should include larger and more representative groups of patients with PD, including individuals at different stages of disease progression. Longitudinal studies are particularly needed to determine whether changes in PA levels lead to changes in functional fitness, or whether patients with better functional capacity are more likely to maintain recommended levels of PA.

Author Contributions: Conceptualization, J.C. (Jaroslaw Cholewa), J.C. (Joanna Cholewa) and A.G.; methodology, J.C. (Jaroslaw Cholewa), J.P., G.M. and A.G.; software, J.C. (Jaroslaw Cholewa), J.P. and G.M.; validation, J.C. (Jaroslaw Cholewa), I.U., J.C. (Joanna Cholewa), J.P., G.M. and A.G.; formal analysis, J.C. (Jaroslaw Cholewa), J.C. (Joanna Cholewa) and A.G.; investigation, J.C. (Jaroslaw Cholewa), J.C. (Joanna Cholewa) and A.G.; data curation, J.C. (Jaroslaw Cholewa) and J.C. (Joanna Cholewa); writing—original draft preparation, J.C. (Jaroslaw Cholewa) and J.C. (Joanna Cholewa);

writing—review and editing, J.C. (Jaroslaw Cholewa)., I.U., J.C. (Joanna Cholewa), J.P., G.M. and A.G.; supervision, J.C. (Jaroslaw Cholewa) and A.G.; project administration, J.C. (Jaroslaw Cholewa). All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Bioethics Committee of the Academy of Physical Education in Katowice (approval no. 30/2017).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

PD	Parkinson's disease
SFT	Senior Fitness Test
SSFT	Synthetic functional fitness index
PA	physical activity
MDS-UPDRS	Movement Disorder Society–Unified Parkinson's Disease Rating Scale
MEDL	Motor Experiences of Daily Living
ME	Motor Examination
MC	Motor Complications
ACSM	American College of Sports Medicine
LED	levodopa equivalent daily dose
MMSE	Mini-Mental State Examination
BDI	Beck Depression Inventory

References

1. Bloem, B.R.; Okun, M.S.; Klein, C. Parkinson's Disease. *Lancet* **2021**, *397*, 2284–2303. [[CrossRef](#)] [[PubMed](#)]
2. Armstrong, M.J.; Okun, M.S. Diagnosis and Treatment of Parkinson Disease: A Review. *JAMA* **2020**, *323*, 548. [[CrossRef](#)] [[PubMed](#)]
3. Soh, S.-E.; Morris, M.E.; McGinley, J.L. Determinants of Health-Related Quality of Life in Parkinson's Disease: A Systematic Review. *Park. Relat. Disord.* **2011**, *17*, 1–9. [[CrossRef](#)] [[PubMed](#)]
4. Schrag, A. What Contributes to Quality of Life in Patients with Parkinson's Disease? *J. Neurol. Neurosurg. Psychiatry* **2000**, *69*, 308–312. [[CrossRef](#)] [[PubMed](#)]
5. Mak, M.K.; Wong-Yu, I.S.; Shen, X.; Chung, C.L. Long-Term Effects of Exercise and Physical Therapy in People with Parkinson Disease. *Nat. Rev. Neurol.* **2017**, *13*, 689–703. [[CrossRef](#)] [[PubMed](#)]
6. Feng, Y.-S.; Yang, S.-D.; Tan, Z.-X.; Wang, M.-M.; Xing, Y.; Dong, F.; Zhang, F. The Benefits and Mechanisms of Exercise Training for Parkinson's Disease. *Life Sci.* **2020**, *245*, 117345. [[CrossRef](#)] [[PubMed](#)]
7. Ernst, M.; Folkerts, A.-K.; Gollan, R.; Lieker, E.; Caro-Valenzuela, J.; Adams, A.; Cryns, N.; Monsef, I.; Dresen, A.; Roheger, M.; et al. Physical Exercise for People with Parkinson's Disease: A Systematic Review and Network Meta-Analysis. *Cochrane Database Syst. Rev.* **2023**, *2023*, CD013856. [[CrossRef](#)] [[PubMed](#)]
8. Domingos, J.; Radder, D.; Riggare, S.; Godinho, C.; Dean, J.; Graziano, M.; De Vries, N.M.; Ferreira, J.; Bloem, B.R. Implementation of a Community-Based Exercise Program for Parkinson Patients: Using Boxing as an Example. *J. Park. Dis.* **2019**, *9*, 615–623. [[CrossRef](#)] [[PubMed](#)]
9. Ferrazzoli, D.; Ortelli, P.; Zivi, I.; Cian, V.; Urso, E.; Ghilardi, M.F.; Maestri, R.; Frazzitta, G. Efficacy of Intensive Multidisciplinary Rehabilitation in Parkinson's Disease: A Randomised Controlled Study. *J. Neurol. Neurosurg. Psychiatry* **2018**, *89*, 828–835. [[CrossRef](#)] [[PubMed](#)]

10. Goetz, C.G.; Tilley, B.C.; Shaftman, S.R.; Stebbins, G.T.; Fahn, S.; Martinez-Martin, P.; Poewe, W.; Sampaio, C.; Stern, M.B.; Dodel, R.; et al. Movement Disorder Society-sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. *Mov. Disord.* **2008**, *23*, 2129–2170. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Cholewa, J.; Cholewa, J.; Nawrocka, A.; Gorzkowska, A. Senior Fitness Test in the Assessment of the Physical Fitness of People with Parkinson's Disease. *Exp. Gerontol.* **2021**, *151*, 111421. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Cancela, J.M.; Ayán, C.; Gutiérrez-Santiago, A.; Prieto, I.; Varela, S. The Senior Fitness Test as a Functional Measure in Parkinson's Disease: A Pilot Study. *Park. Relat. Disord.* **2012**, *18*, 170–173. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Inkster, L.M.; Eng, J.J.; MacIntyre, D.L.; Stoessl, A.J. Leg Muscle Strength Is Reduced in Parkinson's Disease and Relates to the Ability to Rise from a Chair. *Mov. Disord.* **2003**, *18*, 157–162. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Bryant, M.S.; Rintala, D.H.; Hou, J.-G.; Protas, E.J. Relationship of Falls and Fear of Falling to Activity Limitations and Physical Inactivity in Parkinson's Disease. *J. Aging Phys. Act.* **2015**, *23*, 187–193. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Ellis, T.; Cavanaugh, J.T.; Earhart, G.M.; Ford, M.P.; Foreman, K.B.; Dibble, L.E. Which Measures of Physical Function and Motor Impairment Best Predict Quality of Life in Parkinson's Disease? *Park. Relat. Disord.* **2011**, *17*, 693–697. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Mantri, S.; Wood, S.; Duda, J.E.; Morley, J.F. Comparing Self-Reported and Objective Monitoring of Physical Activity in Parkinson Disease. *Park. Relat. Disord.* **2019**, *67*, 56–59. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Gorzkowska, A.; Cholewa, J.; Małeck, A.; Klimkowicz-Mrowiec, A.; Cholewa, J. What Determines Spontaneous Physical Activity in Patients with Parkinson's Disease? *J. Clin. Med.* **2020**, *9*, 1296. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Postuma, R.B.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C.W.; Oertel, W.; Obeso, J.; Marek, K.; Litvan, I.; Lang, A.E.; et al. MDS Clinical Diagnostic Criteria for Parkinson's Disease. *Mov. Disord.* **2015**, *30*, 1591–1601. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Hoehn, M.M.; Yahr, M.D. Parkinsonism: Onset, Progression, and Mortality. *Neurology* **1967**, *17*, 427–442. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease. *Mov. Disord.* **2010**, *25*, 2649–2653. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Folstein, M.F.; Folstein, S.E.; McHugh, P.R. Mini-Mental State. *J. Psychiatr. Res.* **1975**, *12*, 189–198. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Beck, A.T.; Steer, R.A.; Carbin, M.G. Psychometric Properties of the Beck Depression Inventory: Twenty-Five Years of Evaluation. *Clin. Psychol. Rev.* **1988**, *8*, 77–100. [\[CrossRef\]](#)
23. John, D.; Freedson, P. ActiGraph and Actical Physical Activity Monitors: A Peek under the Hood. *Med. Sci. Sports Exerc.* **2012**, *44*, S86–S89. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Terashi, H.; Mitoma, H.; Yoneyama, M.; Aizawa, H. Relationship between Amount of Daily Movement Measured by a Triaxial Accelerometer and Motor Symptoms in Patients with Parkinson's Disease. *Appl. Sci.* **2017**, *7*, 486. [\[CrossRef\]](#)
25. Tucker, P.; Gilliland, J. The Effect of Season and Weather on Physical Activity: A Systematic Review. *Public Health* **2007**, *121*, 909–922. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Ito, H.; Yokoi, D.; Kobayashi, R.; Okada, H.; Kajita, Y.; Okuda, S. The Relationships between Three-Axis Accelerometer Measures of Physical Activity and Motor Symptoms in Patients with Parkinson's Disease: A Single-Center Pilot Study. *BMC Neurol.* **2020**, *20*, 340. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Freedson, P.S.; Melanson, E.; Sirard, J. Calibration of the Computer Science and Applications, Inc. Accelerometer. *Med. Sci. Sports Exerc.* **1998**, *30*, 777–781. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Parkinson's Foundation; American College of Sports Medicine. Parkinson's Exercise Recommendations. Available online: <https://www.parkinson.org/about-us/news/updated-exercise-recommendations> (accessed on 4 May 2026).
29. Rikli, R.E.; Jones, C.J. Development and Validation of Criterion-Referenced Clinically Relevant Fitness Standards for Maintaining Physical Independence in Later Years. *Gerontologist* **2013**, *53*, 255–267. [\[CrossRef\]](#) [\[PubMed\]](#)
30. Bryant, M.S.; Rintala, D.H.; Hou, J.-G.; Protas, E.J. Influence of Fear of Falling on Gait and Balance in Parkinson's Disease. *Disabil. Rehabil.* **2014**, *36*, 744–748. [\[CrossRef\]](#) [\[PubMed\]](#)
31. Urgacz, K.; Cholewa, J.; Uher, I.; Sahin, B.; Cholewa, J. Senior Fitness Test in Assessing the Effectiveness of Physical Rehabilitation in the Context of Parkinson's Disease Patients' Quality of Life. *Phys. Act. Rev.* **2018**, *6*, 110–116. [\[CrossRef\]](#)
32. Cavanaugh, J.T.; Ellis, T.D.; Earhart, G.M.; Ford, M.P.; Foreman, K.B.; Dibble, L.E. Capturing Ambulatory Activity Decline in Parkinson's Disease. *J. Neurol. Phys. Ther.* **2012**, *36*, 51–57. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Uher, I.; Cholewa, J.J.; Kaško, D.; Bernasovska, J.; Balcerzak, W.; Cholewa, J. Holistic Perspectives on Parkinson's Disease: A Comparative Observational Study of Risk Factors. *Aktual. Neurol.* **2025**, *25*, 46. [\[CrossRef\]](#)
34. Staniszewski, M.; Kruszewski, A.; Lopuszanska-Dawid, M. Short-Term Effects of Rock Steady Boxing Exercise on the Balance Ability of People with Parkinson's Disease: An Interventional Experimental Study. *Appl. Sci.* **2025**, *15*, 12107. [\[CrossRef\]](#)

35. Giladi, N.; Nieuwboer, A. Understanding and Treating Freezing of Gait in Parkinsonism, Proposed Working Definition, and Setting the Stage. *Mov. Disord.* **2008**, *23*, S423–S425. [[CrossRef](#)] [[PubMed](#)]
36. Chaudhuri, K.R.; Sauerbier, A.; Rojo, J.M.; Sethi, K.; Schapira, A.H.V.; Brown, R.G.; Antonini, A.; Stocchi, F.; Odin, P.; Bhattacharya, K.; et al. The Burden of Non-Motor Symptoms in Parkinson's Disease Using a Self-Completed Non-Motor Questionnaire: A Simple Grading System. *Park. Relat. Disord.* **2015**, *21*, 287–291. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.